Quantcast
Channel: Australia Headlines on One News Page [United States]
Viewing all 53225 articles
Browse latest View live

Pamela Anderson slams Australian PM for refusing to help Assange

0
0
[USA] Nov 19 (ANI): Pamela Anderson slammed Australian Prime Minister Scott Morrison for rejecting her calls to help WikiLeaks founder Julian Assange come home to Australia. Reported by Sify 2 hours ago.

YG Cussing Out Tekashi 6ix9ine Fan in Australia

0
0
YG's beef with Tekashi69 is going way beyond West Coast vs. East Coast, because he's cussing out 6ix9ine fans thousands of miles away.  We got video of YG boarding a flight in Melbourne, and he starts yelling at a fan who flashes… Reported by TMZ.com 2 hours ago.

CORRECTION - ESS Inc. Appoints Solutions Energy A-Pac Pty Ltd as Company Agents for Australia and New Zealand

0
0
Corrected Version to over-ride press release dated November 16, 2018

PORTLAND, Ore., Nov. 19, 2018 (GLOBE NEWSWIRE) -- ESS Inc., a leading manufacturer of safe, low-cost and long-duration energy storage systems, today announced that it has partnered with Solutions Energy A-Pac Pty Ltd for commercial representation in Australia, New Zealand, Papua New Guinea and East Timor.“We are pleased to welcome Solutions Energy as agents representing the company,” said Craig Evans, founder and CEO of ESS Inc. “The Solutions Energy team is comprised of like-minded experts in the power and clean energy sectors who share in our mission to deliver clean, low-cost, long-duration energy storage systems with the lowest levelized cost of storage (LCOS) on the market.”

With the drive toward carbon-free electricity around the world, and the need for commercial, industrial and utility users to improve resilience and reduce costs, ESS Inc.’s Energy Warehouse™ is an attractive solution. It offers the benefits of low lifetime cost, no hazardous materials or fire risk, unlimited cycling, zero capacity fade and instantaneous response – and long-duration (3+ hour) energy delivery. This capability enables users to optimize solar generation, reduce peak demand, replace peaker plants, improve grid resilience, and provide ancillary services.

“Building awareness and interest in ESS Inc.’s Energy Warehouse™ and new Energy Center – utility-scale solutions for utility-scale applications – will lead to productive working relationships with customers that will keep us on the forefront of the promising long-duration market,” said Drew Williams, Director of Solutions Energy A-Pac Pty Ltd. “We look forward to collaborating on storage applications and projects to become the catalyst for a sustainable energy future in Australasia.”

As part of the Solutions Platform, ESS Inc. is exhibiting at Australian Utility Week at MEC in Melbourne, Victoria, Australia, November 21-22, 2018; Booth #23.  For more information, visit www.australian-utility-week.com/

*About the Energy Warehouse*
Utilizing earth-abundant iron, salt and water for its electrolyte, and simple materials for battery components, the ESS Energy Warehouse is a durable, environmentally safe, long-duration storage solution that is ideally suited for time-shifting renewable energy, managing facility demand charges, and smoothing the intermittency of renewables on a constrained grid. The EW has a lifespan that exceeds 20,000 cycles, low maintenance requirements, and an 8-hour energy capacity. It matches well with the 25-year lifespan of solar and wind projects, supporting those applications’ low levelized cost of energy (LCOE) requirements.

*About Solutions Energy A-Pac Pty Ltd*
Solutions Energy A-Pac Pty Ltd is part of the Solutions Platform, an assets and advisory house based in Melbourne, Australia. First founded in 1997 as Solutions Soft, it has been an advisor in the utilities, sensing and metrology spaces in the Asia-Pacific region.
For more information, visit www.solutionssoft.com.au/

*About ESS Inc.*
Established in 2011, ESS Inc. develops and manufactures the low-cost, long-duration Energy Warehouse^ TM (EW) flow battery for commercial and utility-scale energy storage applications requiring 4+ hours of flexible energy capacity and 20+ years of operating life with no capacity fade. The EW utilizes earth-abundant iron, salt, and water for the electrolyte, and delivers an environmentally safe, long-life energy storage solution for the world’s renewable energy infrastructure with the lowest levelized cost of storage per kWh. For more information visit www.essinc.com.

*Company Contact*
Drew Williams, Director
Solutions Energy A-Pac Pty Ltd
+61 1300 001 205
info@solutionssoft.com.au*Company Contact*
Jessi Lord
Marketing Manager
ESS Inc.
541-598-5485
jessi.lord@essinc.com

*Media Contact*
Eugene Hunt
Trevi Communications for ESS Inc.
978-750-0333 x.101
gene@trevicomm.com

  Reported by GlobeNewswire 1 hour ago.

Payne spruiks 'discretion' on embassy

0
0
Discretion is the better part of valour, Foreign Minister Marise Payne has said about discussions among her colleagues on Australia's Israeli embassy. Reported by SBS 1 hour ago.

Medios AG: Core shareholder mediosmanagement GmbH postpones share placement due to current overall market conditions

0
0
DGAP-News: Medios AG / Key word(s): Miscellaneous

19.11.2018 / 18:00
The issuer is solely responsible for the content of this announcement.
--------------------

Not for publication or distribution in the United States of America, Australia, Canada, Japan or South Africa or in any other jurisdiction in which offers or sales would be prohibited by applicable law.
 

*Corporate News*

*Medios AG: Core shareholder mediosmanagement GmbH postpones share placement due to current overall market conditions *

Berlin, 19 November 2018 - Medios AG ('Medios' or 'Company', ISIN: DE000A1MMCC8, WKN: A1MMCC ticker: ILM1), one of the leading Specialty Pharma companies in Germany, announces that its core shareholder mediosmanagement GmbH has decided to postpone the envisaged share placement, which was pre-announced by Medios on 23 October 2018. This decision has been taken due to the current unfavourable market conditions.

Mediosmanagement GmbH will continue to pursue its strategic target to increase the Company's free float, its presence in the capital market, and the liquidity of its shares, by giving new investors looking for an entry into Medios' stock an access opportunity. Accordingly, the envisaged transaction may take place at a later point in time.

To underpin their long-term commitment and the fact that there is no immediate need to sell any shares at this point in time, mediosmanagement GmbH and Manfred Schneider, Founder and CEO of Medios AG, have signed a 90 day lock up today (subject to market standard customary exemptions).

*About Medios AG*
Medios AG is one of the leading Specialty Pharma companies in Germany. As wholesaler for Specialty Pharma drugs and GMP-certified manufacturer of patient-specific medications, Medios covers substantial elements of the supply chain in this field and follows the highest international quality standards. Specialty Pharma drugs are, in particular, individualised infusions for patients with rare or chronic diseases like cancer, HIV and hepatitis. It is Medios' aim to provide integrated solutions along the value chain to partners and clients, thereby ensuring an optimal pharmaceutical care for patients.

Medios AG is Germany's first listed Specialty Pharma company. The share (WKN: A1MMCC, ISIN: DE000A1MMCC8) is listed in the Regulated Market of the Frankfurt Stock Exchange (General Standard) and Hamburg-Hannover Stock Exchange.

*Contact*
Kirchhoff Consult AG
Nikolaus Hammerschmidt
Borselstraße 20
22765 Hamburg
Germany
Telephone: +49 40 60918618
Fax: +49 40 60918660
E-mail: nikolaus.hammerschmidt@kirchhoff.de
www.kirchhoff.de

*Disclaimer / Important Note*
This release is for informational purposes only and does not constitute an offer or the announcement of a forthcoming offer or solicitation or invitation of any offer to buy any securities or the announcement of a forthcoming solicitation or invitation of any offer to buy any securities in any jurisdiction, including the United States, Australia, Canada or Japan. No securities are offered by or on behalf of Medios AG. This release and the information it contains are not for publication in any jurisdiction in which it would be unlawful.

In line with foreign securities laws, particularly the US Securities Act of 1933, as amended ("Securities Act"), shares of Medios AG have not been registered and will not be registered with foreign securities authorities and in particular may not be offered or sold in the United States of America ("USA") without registration or an exemption from the registration requirements of the Securities Act. This announcement may not be disseminated in the USA and/or within the USA and may not be distributed or forwarded to publications that are widely available in the USA.

In the United Kingdom, this document is only being distributed to and is only directed at persons who (i) are investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) (the "Order") or (ii) are persons falling within Article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc.) of the Order (all such persons together being referred to as "Relevant Persons"). This document is directed only at Relevant Persons and must not be acted on or relied on by persons who are not Relevant Persons. Any investment or investment activity to which this document relates is available only to Relevant Persons and will be engaged in only with Relevant Persons.
--------------------

19.11.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de --------------------

Language: English
Company: Medios AG
Friedrichstraße 113a
10117 Berlin
Germany
Phone: +49 30 232 566 - 800
Fax: +49 30 232 566 - 801
E-mail: ir@medios.ag
Internet: www.medios.ag
ISIN: DE000A1MMCC8
WKN: A1MMCC
Listed: Regulated Market in Frankfurt (General Standard), Hamburg; Regulated Unofficial Market in Dusseldorf
 
End of News DGAP News Service Reported by EQS Group 56 minutes ago.

JAGGAER Recognized as a 2018 Gartner Peer Insights Customers’ Choice for Strategic Sourcing Application Suites

0
0
RESEARCH TRIANGLE PARK, N.C., Nov. 19, 2018 (GLOBE NEWSWIRE) -- JAGGAER, the world’s largest independent spend management company, today announces that customers on Gartner Peer Insights have named JAGGAER a 2018 Gartner Peer Insights Customers’ Choice, based on feedback and ratings from end users of JAGGAER’s products and services. As of November 15, 2018, JAGGAER received more reviews than any other company in this category.Earlier this year JAGGAER (Advantage) was named by Gartner analysts highest for ability to execute in its 2018 “Magic Quadrant for Strategic Sourcing Application Suites,” * and a Leader in Gartner, Inc’s 2018 “Magic Quadrant for Procure-to-Pay Suites.”**
*LINK TO OFFICIAL LANDING PAGE*

JAGGAER feels that our commitment to listening to the customer and incorporating their needs into our solutions is evidenced by the comments published on Gartner’s Peer Insights:

“A robust, compliant but efficient toolbox for delivering complex sourcing activities” *
*Supply Chain Manager in the Energy and Utilities Industry*: *Company Size 500M - 1B USD

“More than a software company” 
Sourcing, Procurement and Vendor Management in the Manufacturing Industry: Company Size: 10B – 30B

“Jaggaer provides modern procurement help in evolving environment” *
*Procurement Manager in the Education Industry*: *Company Size: Gov't/PS/ED
JAGGAER is one of the only companies in the market that offers complete strategic sourcing solutions for any type of business need, from direct to indirect. JAGGAER’s solutions are designed for companies in 70 countries across the globe, to digitally transform their supply chains and handle complex sourcing events. JAGGAER offers the industry’s widest array of spend management solutions, developed specifically for manufacturing, consumer packaged goods, retail, education, healthcare, life sciences, transportation, and public sector, among other industries. 

“JAGGAER feels this distinction represents a validation of the application of innovation to customers’ specific needs. We develop solutions based on actual business use cases, shared by multiple companies in the industries that we serve. Our high level of customer interaction is indicated by the fact that we received more feedback than any other company sampled. From our perspective, our leadership positions in two Gartner reports, coupled with this new distinction, creates a compelling story: we are delivering a full spectrum of specially tuned spend management solutions to accommodate the growth of businesses, from local to global,” says Robert Bonavito, CEO, JAGGAER.

A complimentary copy of the Gartner Magic Quadrant for Strategic Sourcing Application Suites can be downloaded HERE.

A complimentary copy of the Gartner Magic Quadrant for Procure-to-Pay Suites can be downloaded HERE.

*Gartner, “Magic Quadrant for Strategic Sourcing Application Suites”, Magnus Bergfors, Patrick M Connaughton, Desere Edwards, William McNeill, Kaitlynn N. Sommers, 1 August 2018

**Gartner, “Magic Quadrant for Procure-to-Pay Suites”, authored by Desere Edwards, William McNeill, Magnus Bergfors, Patrick M Connaughton, Kaitlynn N. Sommers published 29 May 2018.

*About Peer Insights: *
Peer Insights is an online platform of ratings and reviews of IT software and services that are written and read by IT professionals and technology decision-makers. The goal is to help IT leaders make more insightful purchase decisions and help technology providers improve their products by receiving objective, unbiased feedback from their customers. Gartner Peer Insights includes more than 70,000 verified reviews in more than 200 markets. For more information, please visit www.gartner.com/reviews/home.

Gartner Peer Insights Customers’ Choice constitute the subjective opinions of individual end-user reviews, ratings, and data applied against a documented methodology; they neither represent the views of, nor constitute an endorsement by, Gartner or its affiliates.

*Gartner Disclaimer*
Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner's research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.

*About JAGGAER: Global Source to Pay Spend Management Solutions  *
JAGGAER is the world’s largest independent spend management company, with nearly 2000 customers connected to a network of 3.7 million suppliers in 70 countries, served by offices located in North America, Latin America, throughout Europe, the United Kingdom, Australia, Asia, and the Middle East. JAGGAER offers complete SaaS-based Source to Pay eProcurement solutions with advanced Spend Analytics, Sourcing, Supplier Management, Contract Lifecycle Management, Savings Tracking, and intelligent workflow capabilities. JAGGAER has pioneered spend solutions for over two decades and continues to lead the innovation curve by listening to customers and analyzing the market. Our solution suites are trusted by the world’s largest manufacturing, education, health care, retail, consumer package goods, logistics, construction, utilities companies and public service organizations. Additionally, JAGGAER holds 38 patents–more than any other spend management company. www.JAGGAER.com

To join the conversation, please visit our blog at https://JAGGAER.com/blog/ or follow us on Twitter @JaggaerPro

*JAGGAER MEDIA CONTACT: Steve Lundin*
news@JAGGAER.com
919-659-2601 Reported by GlobeNewswire 26 minutes ago.

Narrowest test cricket wins by runs

0
0
1_West Indies vs Australia, Adelaide, 19932_England vs. Australia, Birmingham, 20053_England vs. Australia, Melbourne, 19823_Australia vs. England, Manchester, 19024_New Zealand vs. Pakistan, Abu Dhabi, 20185_South Africa... Reported by New Zealand Herald 35 minutes ago.

AUD/USD edges lower toward mid-0.72s as DXY advances to 96.50 area

0
0
· *RBA's Lowe says the overall economic picture is positive.*
· *Concerns over a slowdown in China's economy weigh on AUD.*
· *US Dollar Index continues to recover yesterday's losses.*

The AUD/USD came under a heavy selling pressure in the early European morning and fell to a fresh 3-day low at 0.7250 before staging a modest rebound. However, with the greenback gathering strength against its rivals in the NA session, the pair failed to extend its recovery move and was last seen trading at 0.7260, losing 0.45% on a daily basis.

Earlier today, while speaking at the CEDA Annual Dinner in Melbourne, RBA Governor Philip Lowes said that the overall economic picture was positive and that they were moving closer to full employment. Nevertheless, the AUD failed to take advantage of these positive remarks amid concerns over the economic slowdown in Australia's biggest trading partner, China. Chinese Finance Ministry official Tan Long today said that the economic uncertainties and the downward pressure on the economy had both increased.

On the other hand, with major European currencies staying under pressure amid the never-ending political jitters surrounding the UK and Italy, the US Dollar Index gained traction on Tuesday to make it difficult for the pair to reverse its direction. At the moment, the DXY is up 0.35% on the day at 96.50. Meanwhile, today's data from the U.S. showed that housing starts increased 1.5% in October following September's 5.5% decline to provide an additional boost to the buck.

*Technical levels to consider*

The initial support for the pair aligns at 0.7250 (daily low) ahead of 0.7220 (100-DMA/20-DMA) and 0.7185 (Nov. 14 low). On the upside, resistances are located at 0.7300 (psychological level/daily high), 0.7340 (Nov. 16 high) and 0.7380 (Aug. 21 high).

  Reported by FXstreet.com 4 hours ago.

I'm A Celebrity 2018: Why is Ant McPartlin not on I'm A Celebrity this year? Why has Holly Willoughby replaced him? All the details on Declan Donnelly's co-host

0
0
I'm A Celebrity: Ant McPartlin is missing from this year's series [ITV] I'm A Celebrity... Get Me Out Of Here! returned to screens earlier this month for a brand new series. Stars like Fleur East, Harry Redknapp and Emily Atack are on the ITV line-up but another new addition to the jungle this year is presenter Holly Willoughby. The host is fronting the Australia-set show with Declan Donnelly in the absence of Ant McPartlin who is ... Reported by OK! 3 hours ago.

Leigh Halfpenny: Wales full-back to miss South Africa clash due to concussion

0
0
Wales full-back Leigh Halfpenny has been ruled out of Saturday’s clash against South Africa in the Under Armour Series. Halfpenney suffered concussion following a challenge by Australia centre Samu Kerevi when Wales beat the Wallabies 10 days ago. Kerevi escaped sanction following the incident, but Wales have now lost 80 times-capped Halfpenny for the Springboks […] Reported by talkSPORT 3 hours ago.

Global Osseointegration Implants Market 2017-2018 & 2026 Featuring Medtronic, Stryker, Zimmer Biomet, Smith and Nephew, Straumann, Integrum and ConMed

0
0
Dublin, Nov. 20, 2018 (GLOBE NEWSWIRE) -- The "Osseointegration Implants Market Size, Share & Trends Analysis Report By End Use (ASCs, Hospitals, Dental Clinics), By Product (Dental, Knee, Hip, Spinal Implants), By Region, And Segment Forecasts, 2018 - 2026" report has been added to *ResearchAndMarkets.com's* offering.

The global osseointegration implants market size is expected to reach USD 9.3 billion by 2026, registering a CAGR of 7.7% during the forecast period.

Growing number of joint replacement surgeries among geriatric population, rising adoption of minimally invasive surgeries, and advancement in healthcare facilities are anticipated to drive the osseointegration implants market.

Key players have been using different strategies such as new product launch, acquisitions, partnerships, joint ventures, and agreements to increase their foothold in this market. For instance, in April 2018, Integrum SE introduced a revolutionary OPRA implant system. According to the company, the product will be initially available only in London and would be distributed through London International Patient Services (LIPS), a U.K.-based healthcare treatment organization for international patients seeking treatment.

The osseointegration implants market in developed economies, such as U.S., Germany, France, and Australia, is comparatively mature owing to presence of key market players in these countries and high demand for such products.

On the other hand, emerging countries in Asia and Latin America currently have a moderate adoption rate of these products, presenting lucrative growth opportunities in future. Economic growth and rising disposable income in these countries are anticipated to propel market growth. Manufacturing companies have been investing in these rapidly developing markets, provided pricing and distribution activities are undertaken efficiently.

*Further key findings from the report suggest:*

· By product, dental implants are projected to exhibit a remarkable CAGR of nearly 9.0% over the forecast period. This growth can be attributed to large number of patients along with increasing number of dental surgeries, especially in U.S. and Europe
· Asian countries are estimated to witness the highest growth in this market due to increase in penetration of market players, rising disposable income, expanding geriatric population, and surge in road traffic accidents
· Some of the key companies in the market are Medtronic, Stryker Corporation, Zimmer Biomet Holdings, Smith and Nephew Plc., Straumann AG Group, Integrum SE, and ConMed Corporation.

*Key Topics Covered:*

*Chapter 1 Report Scope*
1.1 Segment Market Scope
1.2 Regional Scope
1.3 Estimates and Forecast Timeline

*Chapter 2 Methodology*
2.1 Research Methodology
2.2 Information or Data Analysis
2.3 Market Formulation & Validation
2.4 Region Wise Market Calculation
2.5 Region Based Segment Share Calculation
2.6 Models Used for Market Estimation
2.7 List of Secondary Sources
2.8 List of Primary Sources
2.9 List of Abbreviations

*Chapter 3 Objectives*
3.1 Objective - 1: Understanding the market dynamics
3.2 Objective - 2: Understanding the market estimates and forecasts
3.3 Objective - 3: Understanding the attributes such as strategy framework, competitor categorization
3.4 Objective - 4: Understanding the key end-users, technological, application and product scopes

*Chapter 4 Executive Summary*

*Chapter 5 Market Definition*

*Chapter 6 Industry Outlook*
6.1 Market Segmentation
6.2 Business Segment Trends
6.2.1 Product business analysis
6.2.2 End-use analysis
6.2.3 Regional business analysis
6.3 Market Variable Analysis
6.3.1 Market driver analysis
6.3.1.1 Rising geriatrics with musculoskeletal disorders
6.3.1.2 Increasing incidences of injuries from road traffic accidents
6.3.1.3 Adoption of minimally invasive surgeries
6.3.2 Market restraint analysis
6.3.2.1 High cost of implants
6.3.2.2 Stringent Regulatory Guidelines
6.4 Penetration & Growth Prospect Mapping
6.5 Business Environment Analysis tools
6.5.1 SWOT Analysis, by PEST
6.5.2 Porter's five forces analysis
6.5.3 Industry Analysis - Ansoff'S Matrix

*Chapter 7 Competitive & Vendor Landscape*
7.1 Participant Categorization
7.1.1 Innovators
7.1.1.1 Zimmer Biomet Holdings
7.1.1.2 Medtronic Plc.
7.1.1.3 Smith and Nephew PLc.
7.1.1.4 Stryker Corporation
7.1.1.5 ConMed Corporation
7.2 Strategy Mapping
7.2.1 New Product Launch
7.2.2 Acquisition
7.2.3 Expansion
7.2.4 Partnerships
7.2.5 Marketing & Promotions

*Chapter 8 Osseointegration Implants Market: Product Estimates & Trend Analysis*
8.1 Osseointegration implants market: Product Movement Analysis
8.2 Dental Implants
8.3 Knee Implants
8.4 Hip Implants
8.5 Spinal Implants

*Chapter 9 Osseointegration Implants Market: End-use Movement Analysis*
9.1 Hospitals
9.2 Ambulatory Surgical Centers
9.3 Dental Clinics

*Chapter 10 Regional Outlook*
10.1 Osseointegration Implants Market Share by Region, 2017 & 2026

*Chapter 11 Company Profiles*
11.1 Strategic Framework
11.2 Company Profiles· Medtronic Plc.
· Zimmer Biomet Holdings Inc.
· DentsPly Sirona
· Straumann Group A.G
· Smith and Nephew Plc.
· Stryker Corporation
· ConMed Corporation
· Integrum S.E
· Osstem Implant Co.
· Bicon, LLC

For more information about this report visit https://www.researchandmarkets.com/research/v3pr26/global?w=12
Did you know that we also offer Custom Research? Visit our Custom Research page to learn more and schedule a meeting with our Custom Research Manager.

CONTACT:
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Orthopedic Devices, Dental Reported by GlobeNewswire 3 hours ago.

Injured Ashton out of Australia match as tourists hit by stomach bug

0
0
Injured Ashton out of Australia match as tourists hit by stomach bug England wing Chris Ashton is ruled out of Saturday's match with Australia, who have been struck down with a stomach bug. Reported by BBC News 3 hours ago.

England lose Ashton, Wallabies handling stomach bug

0
0
LONDON (AP) — England wing Chris Ashton will miss playing Australia on Saturday at Twickenham because of a left calf injury.Ashton was injured last weekend during the 35-15 win over Japan. He's out for two weeks, England forwards... Reported by New Zealand Herald 3 hours ago.

Australia hit by sickness bug ahead of England clash with Israel Folau and Bernard Foley doubtful

0
0
David Pocock is also yet to train this week as he nurses a neck problem, but all three could still play on Saturday Reported by Independent 2 hours ago.

Ashton ruled out for England with thigh problem

0
0
Chris Ashton's international comeback has stalled after the England wing was ruled out of Saturday's climax to the autumn series against Australia by a calf problem. Reported by RTE.ie 2 hours ago.

Sport24.co.za | Wallaby stars laid low by sickness as England Test looms

0
0
Australia are waiting anxiously to see whether stars Bernard Foley and Israel Folau recover from illness in time for their one-off Test with England at Twickenham. Reported by News24 2 hours ago.

World T20: India hopes to overcome English pressure

0
0
[West Indies], Nov 20 (ANI): After squeezing past England to ensure top spot in the final Group-A fixture, West Indies will be now up against Australia in the semi-finals of the ICC Women's World Reported by Sify 2 hours ago.

Golden State Urology Announces Dr. Prithipal Sethi’s Designation as UroLift® Center of Excellence

0
0
Designation Recognizes Dr. Prithipal Sethi‘s Commitment to Exemplary Care, Deep UroLift Experience

SACRAMENTO, Calif. (PRWEB) November 20, 2018

Golden State Urology today announced that Dr. Prithipal Sethi has been designated as a UroLift® Center of Excellence. The designation recognizes that Dr. Sethi has achieved a high level of training and experience with the UroLift System and demonstrated a commitment to exemplary care for men suffering from symptoms associated with Benign Prostatic Hyperplasia or BPH.

“With the UroLift System, symptoms of benign prostatic hyperplasia can be treated with a state of art system that provides rapid improvement of symptoms with the ability to wean off long-term medications. This minimally invasive therapy is definitely on its way to becoming the new standard of care for BPH,” said Dr. Sethi

Nearly 40 million men in the United States are affected by BPH. Not to be confused with prostate cancer, BPH occurs when the prostate gland that surrounds the male urethra becomes enlarged with advancing age and begins to obstruct the urinary system. Symptoms of BPH often include interrupted sleep and urinary problems, and can cause loss of productivity, depression and decreased quality of life.

Five-year data from a randomized study shows the UroLift System offers not only rapid improvement, but also durable relief for patients with BPH. After five years, patients treated with the UroLift System continue to experience symptom relief with minimal side effects, with few patients requiring an additional procedure for relief. A second randomized clinical trial called BPH6 demonstrated that the minimally invasive UroLift System compares very well to the reference standard surgery, transurethral resection of the prostate (TURP), with regard to efficacy, and is superior to TURP at preserving sexual function and offering a more rapid recovery.

Medication is often the first-line therapy for enlarged prostate, but relief can be inadequate and temporary. Side effects of medication treatment can include sexual dysfunction, dizziness and headaches, prompting many patients to quit using the drugs. For these patients, the classic alternative is surgery that cuts, heats or removes prostate tissue to open the blocked urethra. While current surgical options can be very effective in relieving symptoms, they can also leave patients with permanent side effects such as urinary incontinence, erectile dysfunction and retrograde ejaculation.

About the UroLift System
NeoTract’s FDA-cleared UroLift System is a novel, minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). The UroLift permanent implants, delivered during a minimally invasive transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue. Clinical data from a pivotal 206-patient randomized controlled study showed that patients with enlarged prostate receiving UroLift implants reported rapid and durable symptomatic and urinary flow rate improvement without compromising sexual function. Patients also experienced a significant improvement in quality of life. Most common adverse events reported include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Most symptoms were mild to moderate in severity and resolved within two to four weeks after the procedure. The UroLift System is available in the U.S., Europe, Australia, Canada, Mexico and South Korea. Learn more at http://www.UroLift.com.

About Golden State Urology and Dr Sethi
Golden State Urology has offices located in Stockton, Lodi, Elk Grove and Sacramento and offers a wide range of services for men and women. Our physicians are dedicated to excellent patient care and experts in the latest care techniques. Our staff is knowledgeable and helpful, and our offices are friendly and warm.

Dr. Prithipal Sethi received his Bachelors of Science degree from University of California Berkeley in Cell and Molecular Biology. He received his medical degree from St. Louis University School of Medicine and completed his residency at Medical College of Wisconsin. He is board certified by the American Board of Urology.

Dr. Sethi started his Urology career in Stockton in 2004. He founded Golden State Urology in 2007 and which has since expanded to include more locations to help provide care to patients residing in Manteca, Stockton, Lodi and Sacramento. Dr. Sethi’s expertise and continued interest in advanced technologies has allowed him to introduce novel treatments to the area. Currently, his practice provides comprehensive services in urological conditions including Prostate Cancer, BPH, Kidney Stones, male and female Incontinence and Erectile Dysfunction. The practice also offers in-house dispensing and path lab services for the convenience of the patient. Golden State Urology was awarded Best of Stockton Awards in the category of Urologist 2018.

Dr. Sethi is a member of the American Urological Association, American Urological Association Western Section, San Joaquin Medical Society, St Louis University Alumni Association and Medical College of Wisconsin Alumni Association.

# # # Reported by PRWeb 2 hours ago.

Enid Urologists, Drs. James Colvert and Jarrett Kruska Named UroLift® Center of Excellence

0
0
Designation Recognizes Drs. James Colvert and Jarrett Kruska’s Commitment to Exemplary Care, Deep UroLift Experience

ENID, Okla. (PRWEB) November 20, 2018

Enid Urology Associates today announced that Dr. James Colvert and Dr. Jarrett Kruska has been designated as UroLift® Centers of Excellence. The designation recognizes that Dr. Colvert and Kruska have achieved a high level of training and experience with the UroLift System and demonstrated a commitment to exemplary care for men suffering from symptoms associated with Benign Prostatic Hyperplasia or BPH.

“The UroLift System is a breakthrough minimally invasive treatment that takes less than an hour and offers multiple benefits for men with enlarged prostate – no cutting, heating, or removal of tissue, minimal downtime, no compromise of sexual function, and no need for continued medications,” said Dr. Kruska. “UroLift has fundamentally changed how we treat patients suffering bothersome BPH symptoms. We are proud to be national leaders in treating patients with this durable and effective treatment” added Dr. Colvert.

Nearly 40 million men in the United States are affected by BPH. Not to be confused with prostate cancer, BPH occurs when the prostate gland that surrounds the male urethra becomes enlarged with advancing age and begins to obstruct the urinary system. Symptoms of BPH often include interrupted sleep and urinary problems, and can cause loss of productivity, depression and decreased quality of life.

Five-year data from a randomized study shows the UroLift System offers not only rapid improvement, but also durable relief for patients with BPH. After five years, patients treated with the UroLift System continue to experience symptom relief with minimal side effects, with few patients requiring an additional procedure for relief. A second randomized clinical trial called BPH6 demonstrated that the minimally invasive UroLift System compares very well to the reference standard surgery, transurethral resection of the prostate (TURP), with regard to efficacy, and is superior to TURP at preserving sexual function and offering a more rapid recovery.

Medication is often the first-line therapy for enlarged prostate, but relief can be inadequate and temporary. Side effects of medication treatment can include sexual dysfunction, dizziness and headaches, prompting many patients to quit using the drugs. For these patients, the classic alternative is surgery that cuts, heats or removes prostate tissue to open the blocked urethra. While current surgical options can be very effective in relieving symptoms, they can also leave patients with permanent side effects such as urinary incontinence, erectile dysfunction and retrograde ejaculation.

About the UroLift System
NeoTract’s FDA-cleared UroLift System is a novel, minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). The UroLift permanent implants, delivered during a minimally invasive transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue. Clinical data from a pivotal 206-patient randomized controlled study showed that patients with enlarged prostate receiving UroLift implants reported rapid and durable symptomatic and urinary flow rate improvement without compromising sexual function. Patients also experienced a significant improvement in quality of life. Most common adverse events reported include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Most symptoms were mild to moderate in severity and resolved within two to four weeks after the procedure. The UroLift System is available in the U.S., Europe, Australia, Canada, Mexico and South Korea. Learn more at http://www.UroLift.com. Reported by PRWeb 2 hours ago.

Megan McKenna flaunts bikini body as she goes make-up free in Australia during stint on I'm A Celebrity's Extra Camp

0
0
Megan Mckenna took some time off in Australia  [Splash] Megan McKenna flaunted her sensational bikini body during her stint on I'm A Celebrity... Get Me Out Of Here!'s Extra Camp in Australia. Joining the show as a guest alongside hosts Scarlett Moffatt, Joel Dommett and Joe Swash, the former The Only Way Is Essex star has returned to our ITV screens. And taking a break from filming, the 26 year old made the most of her sunnier surroundings as she relaxed poolside ... Reported by OK! 1 hour ago.
Viewing all 53225 articles
Browse latest View live




Latest Images